Loading... Please wait... Loading... Please wait...
ESTIMATED
05/08/2024
05/08/2024
(AS OF MARCH 31)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.10 | -$0.10 | -$0.10 |
| Q2 2024 | 5 | -$0.36 | $0.23 | -$0.10 |
| Q3 2024 | 1 | -$0.10 | -$0.10 | -$0.10 |
| Q4 2024 | 1 | -$0.14 | -$0.14 | -$0.14 |
| Q1 2025 | 2 | -$0.12 | -$0.12 | -$0.12 |
| Q2 2025 | 2 | -$0.14 | -$0.14 | -$0.14 |
| Q3 2025 | 2 | -$0.11 | -$0.11 | -$0.11 |
| Q4 2025 | 2 | -$0.19 | -$0.19 | -$0.19 |
| Q1 2026 | 1 | -$0.28 | -$0.28 | -$0.28 |
| Q2 2026 | 1 | -$0.28 | -$0.28 | -$0.28 |
| Q3 2026 | 1 | -$0.28 | -$0.28 | -$0.28 |
| Q4 2026 | 1 | -$0.29 | -$0.29 | -$0.29 |
CytomX Therapeutics, Inc. last posted its earnings results on Wednesday, May 8th, 2024. The company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of $-0.08 by $0.25. The company had revenue of 41.46 M for the quarter and had revenue of 101.21 M for the year. CytomX Therapeutics, Inc. has generated $0 earnings per share over the last year ($-0.0077 diluted earnings per share) and currently has a price-to-earnings ratio of 6.4. CytomX Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/08/2024 | Q1 2024 | -$0.08 | $0.17 | 0.25 | $19.35 M | $41.46 M | 03/11/2024 | Q4 2023 | $0.00 | $0.01 | 0.01 | $19.60 M | $26.61 M | 11/07/2023 | Q3 2023 | -$0.19 | $0.04 | 0.23 | $26.38 M | 08/08/2023 | Q2 2023 | -$0.19 | -$0.02 | 0.17 | $24.72 M | 05/09/2023 | Q1 2023 | -$0.16 | -$0.01 | 0.15 | $19.91 M | $23.50 M | 03/27/2023 | Q4 2022 | -$0.21 | -$0.40 | -0.19 | $18.07 M | $946,000 | 11/08/2022 | Q3 2022 | -$0.32 | -$0.34 | -0.02 | $16.92 M | 08/04/2022 | Q2 2022 | -$0.36 | -$0.36 | 0 | $18.17 M | 05/05/2022 | Q1 2022 | -$0.35 | -$0.36 | -0.01 | $17.14 M | 03/01/2022 | Q4 2021 | -$0.25 | -$0.40 | -0.15 | $19.57 M | $19.73 M | 11/04/2021 | Q3 2021 | -$0.30 | -$0.35 | -0.05 | $18.38 M | $17.59 M | 08/05/2021 | Q2 2021 | -$0.26 | -$0.30 | -0.04 | $16.96 M | $16.29 M | 05/06/2021 | Q1 2021 | -$0.29 | -$0.26 | 0.03 | $15.97 M | 02/24/2021 | Q4 2020 | -$0.35 | -$0.32 | 0.03 | $16.09 M | $16.37 M | 11/05/2020 | Q3 2020 | -$0.36 | -$0.32 | 0.04 | $17.14 M | $17.79 M | 08/06/2020 | Q2 2020 | $0.34 | -$0.34 | -0.68 | $52.99 M | $16.61 M | 05/07/2020 | Q1 2020 | -$0.46 | $0.27 | 0.73 | $49.59 M | 02/27/2020 | Q4 2019 | -$0.55 | -$0.78 | -0.23 | $17.37 M | $8.28 M | 11/07/2019 | Q3 2019 | -$0.39 | -$0.52 | -0.13 | $18.07 M | $10.71 M | 08/07/2019 | Q2 2019 | -$0.55 | -$0.64 | -0.09 | $16.58 M | $9.01 M |
|---|
A. CytomX Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based off last year's report dates.
A. In the previous quarter, CytomX Therapeutics, Inc. (NASDAQ:CTMX) reported $0.17 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.08 by $0.25.
A. The conference call for CytomX Therapeutics, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for CytomX Therapeutics, Inc.'s latest earnings report can be read online.
A. CytomX Therapeutics, Inc. (NASDAQ:CTMX) has a recorded annual revenue of $101.21 M.
A. CytomX Therapeutics, Inc. (NASDAQ:CTMX) has a recorded net income of $101.21 M. CytomX Therapeutics, Inc. has generated $-0.0077 earnings per share over the last four quarters.
A. CytomX Therapeutics, Inc. (NASDAQ:CTMX) has a price-to-earnings ratio of 6.4 and price/earnings-to-growth ratio is 0.23.
